The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Chronic Proton Pump Inhibitor Therapy and the Risk of Colorectal Cancer
Open accessAbstract
Background & aims Chronic acid suppression by proton pump inhibitor therapy can lead to hypergastrinemia. Because existing evidence suggested an association between hypergastrinemia and colorectal cancer, we examined whether long-term proton pump inhibitor use is associated with an increased risk of colorectal cancer in a population-representative cohort.Methods We conducted a nested case-control study among patients 50 years of age and older and with > or =5 years of colorectal cancer-free initial follow-up in the General Practice Research Database (1987-2002) from the United Kingdom. Cases consisted of all patients with an incident diagnosis of colorectal cancer. Using incidence density sampling, up to 10 controls were matched with each case on practice site and both duration and calendar time of follow-up before the index date. The primary exposure of interest was > or =5 years of cumulative proton pump inhibitor therapy. We assessed the presence of duration-response and dose-response effects.Results We identified 4432 incident colorectal cancer cases and 44,292 controls. The adjusted odds ratio for > or =5 years of proton pump inhibitor exposure was 1.1 (95% confidence interval, 0.7-1.9). Among high-dose proton pump inhibitor users (ie, > or =1.5 defined daily doses/day), there was a nonstatistically significant trend toward an increased risk with increasing duration of use (test for trend, P = .2). However, patients with pernicious anemia were not at increased risk for colorectal cancer (adjusted odds ratio, 0.9; 95% confidence interval, 0.6-1.3).Conclusions Long-term proton pump inhibitor therapy at a regular dose is not associated with a significantly increased risk of colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, it is fundamental to highlight that many studies over the years have not found a direct correlation between PPI use in clinical practice and an increased risk of CRC[154-156].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prophylactic aspirin and risk of peptic ulcer bleeding
Weil, J., Colin-Jones, D. G., Langman, M. J. S., Lawson, D. H., Logan, R., Murphy, M. S., Rawlins, M. D., Vessey, M. P., & Wainwright, P. (1995) · BMJ · doi:10.1136/bmj.310.6983.827 · Cited by 563
Klinkenberg–Knol, E. C., Nelis, F. G., Dent, J., Snel, P., Mitchell, B., Prichard, P. J., Lloyd, D., Havu, N., Frame, M. H., Román, J., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70135-1 · Cited by 533
The Read clinical classification.
Chisholm, J. (1990) · BMJ · doi:10.1136/bmj.300.6732.1092 · Cited by 504
Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety
Klinkenberg–Knol, E. C., Festen, H. P. M., Jansen, J. B. �. �., Lamers, C. B. H. W., Nelis, F., Snel, P., Luckers, A., Dekkers, C. P. M., Havu, N., & Meuwissen, S. G. M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-3-199408010-00001 · Cited by 422
Biased Selection of Controls for Case-Control Analyses of Cohort Studies
Lubin, J. H., & Gail, M. H. (1984) · Biometrics · doi:10.2307/2530744 · Cited by 414
García Rodríguez, L. A., & Huerta-Alvarez, C. (2001) · Epidemiology · doi:10.1097/00001648-200101000-00015 · Cited by 359
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Yang, Y., Hennessy, S., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.011 · Cited by 350
Self-citationLewis, J. D., Bilker, W. B., Weinstein, R. B., & Strom, B. L. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1115 · Cited by 342
Self-citationGrowth-Promoting Effects of Glycine-Extended Progastrin
Seva, C., Dickinson, C. J., & Yamada, T. (1994) · Science · doi:10.1126/science.8023165 · Cited by 337
Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
Lamberts, R., Creutzfeldt, W., Strüber, H. G., Brunner, G. H. G., & Solcia, E. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90344-c · Cited by 322
Processing and proliferative effects of human progastrin in transgenic mice.
Wang, T. C., Koh, T. J., Varró, A., Cahill, R., Dangler, C. A., Fox, J. G., & Dockray, G. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118993 · Cited by 299
Use of Statins and Risk of Fractures
van Staa, T. P. (2001) · JAMA · doi:10.1001/jama.285.14.1850 · Cited by 272
Gastrin and colorectal cancer: A prospective study
Thorburn*, C. M., Friedman‡, G. D., Dickinson§, C. J., Vogelman∥, J. H., Orentreich∥, N., & Parsonnet*, #. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70193-3 · Cited by 267
The Physiology of Gastric Acid Secretion
Epstein, F. H., Wolfe, M. M., & Soll, A. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812293192605 · Cited by 239
Koh, T. J., Goldenring, J., Ito, S., Mashimo, H. L., Kopin, A. S., Varró, A., Dockray, G., & Wang, T. C. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70199-9 · Cited by 236
Risk of colorectal cancer in adenoma‐bearing individuals within a defined population
Eide, T. J. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910380205 · Cited by 235
The General Practice Research Database: quality of morbidity data.
Hollowell, J. (1997) · PubMed · Cited by 231
de Abajo, F. J., & Rodríguez, L. A. G. (2001) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-1-1 · Cited by 189
Hirschowitz, B. I., Griffith, J., Pellegrin, D., & Cummings, O. W. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90787-y · Cited by 184
Koh, T. J., Dockray, G. J., Varró, A., Cahill, R., Dangler, C. A., Fox, J. G., & Wang, T. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4910 · Cited by 161
Bashford, J. N. R., Norwood, J., & Chapman, S. (1998) · BMJ · doi:10.1136/bmj.317.7156.452 · Cited by 145
Who is using chronic acid suppression therapy and why?
Jacobson, B. C., Ferris, T. G. G., Shea, T. L., Mahlis, E. M., Lee, T. H.-Y., & Wang, T. C. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07186.x · Cited by 143
Pentagastrin stimulates in vitro growth of normal and malignant human colon epithelial cells
Sirinek, K. R., Levine, B. A., & Moyer, M. P. (1985) · The American Journal of Surgery · doi:10.1016/s0002-9610(85)80006-4 · Cited by 120
Jansen, J. B. �. �., Klinkenberg–Knol, E. C., Meuwissen, S. G. M., de Bruijne, J. W., Festen, H. P. M., Snel, P., Ae, L., Biemond, I., & Lamers, C. B. H. W. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90946-x · Cited by 116
The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin
Watson, S. A., Durrant, L. G., Crosbie, J., & Morris, D. L. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430425 · Cited by 106
Elevated gastrin levels in patients with colon cancer or adenomatous polyps
Smith, J. P., Wood, J. G., & Solomon, T. E. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01536047 · Cited by 104
Using prescription claims data for drugs available over‐the‐counter (OTC)
Yood, M. U., Campbell, U. B., Rothman, K. J., Jick, S. S., Lang, J. M., Wells, K. E., Jick, H., & Johnson, C. C. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1454 · Cited by 102
Chronic endogenous hypergastrinemia in humans: Evidence for a mitogenic effect on the colonic mucosa
Laurent‐Puig, P., Sobhani, I., Lehy, T., Cadiot, G., Ruszniewski, P. B., & Mignon, M. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90006-x · Cited by 100
Meier, C. R., Schmitz, S., & Jick, H. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.5.303.33189 · Cited by 99
Singh, P., Owlia, A., Varró, A., Dai, B., Rajaraman, S., & Wood, T. G. (1996) · PubMed · Cited by 98
Smith, A. M., & Watson, S. A. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00842.x · Cited by 98
Metz, D. C., Strader, D. B., Orbuch, M., Koviack, P. D., Feigenbaum, K. M., & Jensen, R. T. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00140.x · Cited by 91
Watson, S., & Smith, A. M. (2001) · PubMed · Cited by 89
McWilliams, D. F., Watson, S. A., Crosbee, D. M., Michaeli, D., & Seth, R. (1998) · Gut · doi:10.1136/gut.42.6.795 · Cited by 87
Long-term maintenance treatment of reflux esophagitis with omeprazole
Koop, H., & Arnold, R. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01297018 · Cited by 74
Serum gastrin levels during long‐term omeprazole treatment
Koop, H., KLEIN, M., & Arnold, R. (1990) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1990.tb00457.x · Cited by 70
Lind, T., Cederberg, C., Forssell, H., Olausson, M., & Olbe, L. C. (1988) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528809090202 · Cited by 69
Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia
Renga, M., Brandi, G., Paganelli, G. M., Calabrese, C., Papa, S., Tosti, A., Tomassetti, P., Miglioli, M., & Biasco, G. (1997) · Gut · doi:10.1136/gut.41.3.330 · Cited by 66
Malignant Polyps: Are They Sheep in Wolves' Clothing?
Koretz, R. L. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-1-199301010-00011 · Cited by 63
Elevated Serum Gastrin Levels in Patients with Colorectal Neoplasia
Seitz, E., Giovannini, M. F., Gouvernet, J., & Gautheir, A. P. (1991) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199110000-00013 · Cited by 58
Risk for Colorectal Adenocarcinoma in Pernicious Anemia
Talley, N. J., Chute, C. G., Larson, D. E., Epstein, R., Lydick, E. G., & Melton, L. J. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-9-738 · Cited by 58
Brunner, G. H. G., & Creutzfeldt, W. (1989) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528909091254 · Cited by 57
Serum levels of gastrin in patients with colorectal neoplasia
Suzuki, H., Matsumoto, K., & Terashima, H. (1988) · Diseases of the Colon & Rectum · doi:10.1007/bf02552592 · Cited by 52
Singh, P., Xu, Z., Dai, B., Rajaraman, S., Rubin, N. H., & Dhruva, B. (1994) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1994.266.3.g459 · Cited by 52
Orbuch, M., Venzon, D. J., Lubensky, I. A., Weber, H. C., Gibril, F., & Jensen, R. T. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02282349 · Cited by 51
Hospital formularies: need for continuous intervention.
Feely, J., Chan, R., Cocoman, L., Mulpeter, K., & O'Connor, P. (1990) · BMJ · doi:10.1136/bmj.300.6716.28 · Cited by 49
Yapp, R. G., Modlin, I. M., Kumar, R. R., Binder, H. J., & Dubrow, R. (1992) · Digestive Diseases and Sciences · doi:10.1007/bf01307566 · Cited by 48
Serum gastrin is not higher in subjects with colonic neoplasia.
Kikendall, J. W., Ar, G., Lh, S., & Bowen, P. E. (1992) · PubMed · Cited by 44
Roles of gastrointestinal hormones in pancreatic cancer
Guo, Y.-S., & Townsend, C. M. (2000) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340070049 · Cited by 28
Jones, R. G., & Page, K. (1990) · BMJ · doi:10.1136/bmj.300.6737.1467-a · Cited by 24
Characterization of cloned human cholecystokinin-B receptor as a gastrin receptor
Akira, M., Shinobu, M., & Kawashima, H. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90332-8 · Cited by 23
Gastrin-mediated effects of omeprazole on rat colon mucosa
Klingensmith, M. E., Neville, L. J., Delpire, E. J., Wolfe, M. M., & Soybel, D. I. (1999) · Surgery · doi:10.1016/s0039-6060(99)70165-0 · Cited by 16
Cited by
Sorted by citations
Complications of Proton Pump Inhibitor Therapy
Vaezi, M. F., Yang, Y., & Howden, C. W. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.047 · Cited by 484
Self-citationControl of Gastric Acid Secretion in Health and Disease
Schubert, M. L., & Peura, D. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.021 · Cited by 493
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shi, S., & Klotz, U. E. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0538-y · Cited by 314
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
Sheen, E., & Triadafilopoulos, G. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1560-3 · Cited by 316
Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia
Sarkar, M., Hennessy, S., & Yang, Y. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00005 · Cited by 301
“A previously published validation study found that data on prescription nonsteroidal anti-inflammatory drugs or aspirin recorded in GPRD correctly classified status of long-term nonsteroidal anti-inflammatory drugs or aspirin in greater than 98% of the GPRD participants (16).”
MethodSelf-citation
Metadata
- Authors
- Yang, Y., Hennessy, S., Propert, K., Hwang, W., Sedarat, A., & Lewis, J. D.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Yang, Yu–Xiao
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 133
- Issue
- 3
- Pages
- 748-754
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2154036780
- Cited by
- 125
- References
- 53
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 7 · 2022: 1 · 2021: 7 · 2020: 16 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 5 · 2014: 3 · 2013: 9 · 2012: 8
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK062978)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Keywords
- proton pump inhibitors, colorectal cancer, hypergastrinemia, acid suppression, long-term drug use, pernicious anemia, dose-response relationship, cancer risk
- MeSH terms
- Adenocarcinoma, Aged, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Gastroesophageal Reflux, United Kingdom, Humans, Longitudinal Studies, Male, Middle Aged, Risk Factors, Time Factors, Colorectal Neoplasms, Case-Control Studies, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
